Blog
About

  • Record: found
  • Abstract: found
  • Article: not found

The role of bcl-2 expression in breast carcinomas (Review).

Oncology Reports

Treatment Outcome, Breast, metabolism, Breast Neoplasms, mortality, pathology, therapy, Epithelial Cells, Female, Genes, bcl-2, Humans, Neoplasm Invasiveness, Prognosis, Proto-Oncogene Proteins c-bcl-2, biosynthesis, Survival Analysis

Read this article at

ScienceOpenPubMed
Bookmark
      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

      Abstract

      The proto-oncogene bcl-2 is demonstrated to block a final common pathway leading to apoptosis and is expressed in more than half of human breast cancers. Invasive breast cancer has reduced bcl-2 immunostaining compared with normal breast epithelia and preinvasive breast lesions. As an inhibitor of apoptosis, bcl-2 should correlate with highly aggressive tumor biology and resistance to hormonal/cytotoxic therapy. However, high bcl-2 expression has been shown to associate with a number of favorable prognostic factors including ER positivity, PgR positivity, low histological grade, well-differentiated tumor, absence of c-erbB-2 and p53. Unexpectedly, numerous studies have shown that tumors with high bcl-2 expression are more responsive to hormone therapy and have more favorable disease-free and overall survival. The clinical significance of bcl-2 in tumorigenesis and prognosis of breast carcinomas from the data recently published are reviewed. Its role in modulation of hormonal/cytotoxic therapy and future directions are also discussed.

      Related collections

      Author and article information

      Journal
      9683837

      Comments

      Comment on this article